MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB

BACKGROUND: MEK and BRAF inhibitors are increasingly common treatments for pediatric nervous system tumors. While effective in blocking Ras/Raf/MEK/ERK pathway activation driving tumor progression, the side effect profile differs from traditional cytotoxic chemotherapies. Little data exists on overl...

Full description

Saved in:
Bibliographic Details
Published in:Neuro Oncol
Main Authors: Winzent, Shelby, Sabus, Ashley, Hemenway, Molly, Nellan, Anandani, Mulcahy-Levy, Jean
Format: Artigo
Language:Inglês
Published: Oxford University Press 2020
Subjects:
Preclinical Models/Experimental Therapy/Drug Discovery
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7715474/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa222.578
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items